GPCR Structure (Seven-Transmembrane Receptors)

Core Concept

G-protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors — roughly 800 genes in humans — and share a common architecture: a single polypeptide that snakes through the plasma membrane seven times as α-helices, with an extracellular N-terminus and an intracellular C-terminus. Ligands as diverse as photons, odorants, neurotransmitters, hormones, and ions bind the receptor, which then changes shape to activate an intracellular heterotrimeric G protein. GPCRs are the target of an estimated one-third of all marketed drugs, making their structure and activation mechanism central to both cell biology and pharmacology.

Key Components

• Seven transmembrane α-helices (TM1–TM7): the defining structural motif; they form a bundle with a ligand-binding pocket.
• N-terminus: extracellular; can be large and glycosylated; contributes to ligand capture in some families.
• Extracellular loops (ECL1–3): connect TM helices outside the cell; ECL2 often lines the binding pocket.
• Intracellular loops (ICL1–3) + C-terminus: the G-protein-binding surface (especially ICL2/ICL3 and the C-tail) and sites for phosphorylation (regulation/desensitization).
• Ligand-binding pocket: usually within the TM bundle (for small ligands); peptide/odorant ligands may engage the N-terminus and ECLs.
• Classes: Class A (rhodopsin-like — largest), Class B (secretin/glucagon), Class C (glutamate/mGluR, GABA_B; often obligate dimers), Class F (Frizzled/Smoothened).
• Arrestins: proteins that bind phosphorylated GPCRs to desensitize/internalize them (and sometimes signal independently).

Mechanism / How It Works

1. A ligand (e.g., epinephrine for the β2-adrenergic receptor, or a photon for rhodopsin) binds within or near the TM bundle.
2. Binding causes the helices to rearrange — most notably an outward movement of TM6 (and TM5) on the intracellular side, opening a cleft for G protein.
3. This activated conformation exposes surfaces on ICL2/ICL3 and the C-terminus that bind and activate a heterotrimeric G protein (see G-protein note), acting as a guanine-nucleotide exchange factor (GEF).
4. The activated G protein dissociates into Gα-GTP and Gβγ, each of which regulates downstream effectors.
5. GPCR kinases (GRKs) phosphorylate the activated receptor, recruiting β-arrestin, which uncouples the receptor from G proteins (desensitization) and promotes internalization — terminating or redirecting the signal.
6. Some GPCRs show constitutive (ligand-independent) activity, and inverse agonists suppress this basal activity — important for drug design.

Energy and Directionality

The receptor itself does not hydrolyze ATP or GTP; it is a catalyst of nucleotide exchange. The energetic cost and directionality come from the GTP cycle of the G protein (GTP binding → hydrolysis) and from downstream effectors (cAMP synthesis consumes ATP). Signal flow is directional — ligand → receptor conformation → G protein → effector → response — and is made reversible by GRK/arrestin desensitization and G-protein GTP hydrolysis, which reset the system.

Experimental Evidence / Technique

• Hydropathy analysis + biochemistry: the seven hydrophobic stretches predicted 7TM helices, confirmed by sequencing and topology mapping.
• X-ray crystallography / cryo-EM: high-resolution structures (rhodopsin 2000; β2-adrenergic receptor 2011 by Kobilka/Lefkowitz — 2012 Nobel Prize) revealed the TM bundle, ligand pocket, and the outward TM6 movement on activation.
• Fluorescence/FRET and spectroscopy: measured real-time conformational changes in TM6 upon agonist binding.
• GTPγS binding assays: agonist-stimulated G-protein activation is quantified as non-hydrolyzable GTPγS incorporation.
• Mutagenesis: point mutations in the TM pocket alter ligand affinity/specificity; "constitutively active" mutants (in TM3/ICL3) lock the receptor "on," mapping the activation switch.

How it works

1. A ligand (e.g., epinephrine for the β2-adrenergic receptor, or a photon for rhodopsin) binds within or near the TM bundle.
2. Binding causes the helices to rearrange — most notably an outward movement of TM6 (and TM5) on the intracellular side, opening a cleft for G protein.
3. This activated conformation exposes surfaces on ICL2/ICL3 and the C-terminus that bind and activate a heterotrimeric G protein (see G-protein note), acting as a guanine-nucleotide exchange factor (GEF).
4. The activated G protein dissociates into Gα-GTP and Gβγ, each of which regulates downstream effectors.
5. GPCR kinases (GRKs) phosphorylate the activated receptor, recruiting β-arrestin, which uncouples the receptor from G proteins (desensitization) and promotes internalization — terminating or redirecting the signal.
6. Some GPCRs show constitutive (ligand-independent) activity, and inverse agonists suppress this basal activity — important for drug design.

Common confusions

• "GPCRs pump ions or act as enzymes themselves." — They are receptors that activate G proteins; any ion movement is via the G protein/effectors (an exception: some GPCRs directly gate GIRK channels via Gβγ).
• "The N-terminus is intracellular." — The N-terminus is extracellular; the C-terminus and intracellular loops face the cytoplasm.
• "One GPCR binds only one type of ligand." — Families are poly-specific (e.g., adrenergic receptors bind epinephrine and norepinephrine); some are promiscuous (odorant receptors).
• "GPCRs always need a ligand to be active." — Many show constitutive activity, which inverse agonists reduce.
• "Ligand binding means the receptor is permanently on." — The receptor is quickly turned off by GRK phosphorylation and arrestin, enabling graded, repeated signaling.

Quick review

• 7TM architecture: N-out, C-in, 3 extracellular + 3 intracellular loops.
• Ligand → TM rearrangement (TM6 outward) → G-protein binding (GEF) → signaling.
• Classes A/B/C/F; ligands span light, odorants, transmitters, hormones, ions.
• ~800 genes; ~1/3 of drugs act on GPCRs.
• Desensitization via GRK + β-arrestin.
• Structures solved for rhodopsin and β2AR (Nobel 2012).